Cargando…
Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has shown favorable results in the treatment of hematological malignancies. Despite the use of post-transplant cyclophosphamide (PTCy), graft versus host disease (GVHD) remains as one of the main complications in this setting. Since...
Autores principales: | Solán, Laura, Carbonell, Diego, Muñiz, Paula, Dorado, Nieves, Landete, Elena, Chicano-Lavilla, María, Anguita, Javier, Gayoso, Jorge, Kwon, Mi, Díez-Martín, José Luis, Martínez-Laperche, Carolina, Buño, Ismael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933467/ https://www.ncbi.nlm.nih.gov/pubmed/33679728 http://dx.doi.org/10.3389/fimmu.2021.516078 |
Ejemplares similares
-
ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide
por: Solán, Laura, et al.
Publicado: (2019) -
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation
por: Muñiz, Paula, et al.
Publicado: (2022) -
Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide
por: Muñiz, Paula, et al.
Publicado: (2021) -
Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms
por: Vallejo, Miren, et al.
Publicado: (2022) -
Short Tandem Repeats (STRs) as Biomarkers for the Quantitative Follow-Up of Chimerism after Stem Cell Transplantation: Methodological Considerations and Clinical Application
por: Navarro-Bailón, Almudena, et al.
Publicado: (2020)